GLP1R and fatty liver disease: A recent study reported the effect on liver steatosis by SGLT2i [36,37,38], but, the change in CAP was 0.27 ± 27.9 in patients without using SGLT2i or GLP-1 RA vs. 1.26 ± 25.1 in patients with using SGLT2i, p = 0.599 (Kruskal–Wallis test).